Denice Torres - 05 Jun 2025 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
Director
Signature
/s/ Sam Martin, attorney-in-fact for Denice Torres
Issuer symbol
CLDX
Transactions as of
05 Jun 2025
Transactions value $
$0
Form type
4
Filing time
09 Jun 2025, 16:12:53 UTC
Previous filing
15 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Torres Denice Director C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON /s/ Sam Martin, attorney-in-fact for Denice Torres 09 Jun 2025 0001820278

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Non-Qualified Stock Option (right to buy) Award $0 +33,000 $0 33,000 05 Jun 2025 Common Stock 33,000 $19.53 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2 Such option vests in three equal annual installments beginning June 5, 2026.